Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share transmission routes, leading to significant co-infection rates (approximately one-third of HIV-infected individuals).
• Effective antiretroviral therapy has improved longevity for HIV patients, shifting mortality causes from AIDS-related illnesses to HCV complications like cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC).

Purpose of the Study:

• To analyze the complex management of HIV/HCV co-infection, with a specific focus on the challenges posed by the presence of hepatocellular carcinoma (HCC).
• To highlight the specialized considerations required for co-infected patients undergoing HCC treatment, including therapeutic regimen interactions and immunosuppressive agent selection.

Main Methods:

• This minireview synthesizes current knowledge on managing HIV/HCV co-infection in the context of HCC.
• Analysis of therapeutic protocols, drug interactions, and immunosuppression strategies relevant to co-infected patients.

Main Results:

• Co-infected patients with HCC follow similar therapeutic protocols to mono-infected individuals but require careful management of unique issues.
• Key challenges include potential drug-drug interactions between antiretroviral and anti-HCV therapies, decisions regarding therapy withdrawal, and the judicious selection of immunosuppressive agents.

Conclusions:

• Management of HIV/HCV co-infection with HCC demands a multidisciplinary and individualized approach.
• Specialist expertise is essential to navigate treatment complexities, optimize patient outcomes, and mitigate risks associated with co-infection and HCC.